1 August 2022
Prague, Czechia – Men who experience behavior changes including apathy or having false beliefs and perceptions in later life are at risk of faster cognitive decline than women, according to new research. A study in the Journal of Alzheimer’s Disease, led by Charles University, in collaboration with the University of Exeter and King’s College London, looked at changes in behavior in cognitively healthy people aged 50 and older, which have previously been linked to a higher risk of developing brain problems.
These behavioral changes are collectively known as mild behavioral impairment (MBI), and encompass symptoms across five domains: apathy or social withdrawal; changes in mood and anxiety; being more impulsive than usual; being socially inappropriate; and having false beliefs or hallucinations (so called psychotic symptoms).
Observing these changes may help physicians and researchers to identify people at a higher risk of developing dementia later in life.
The study is the first to investigate gender differences in the link between these behavioral changes and brain decline. The researchers found that men who exhibit MBI symptoms are at risk of faster cognitive decline compared to women, particularly when psychotic symptoms or symptoms of decreased motivation occur.
Dr. Katrin Wolfová, a PhD student at Charles University in Prague, is the first author of the study. She said: “Observing change in certain behavioral traits can help us to identify people who might already have a neurodegenerative disease before their cognitive functions decline. Being aware of differences between men and women in risk of developing dementia based on these behaviors is important for clinicians as well as researchers.”
Previous research suggests that possible explanations of these findings might be related to structural differences in entorhinal and hippocampal regions of brain, functional differences in serotonergic system, or unequal distribution of types of dementia in men and women.
The research team, which also involved collaborators from Norway and Canada, studied more than 8,000 people enrolled in the British online cohort “Platform for Research Online to Investigate Genetics and Cognition in Aging” (PROTECT) study, led by the University of Exeter and King’s College London. The participants were on average 63 years old and 73 per cent of them were women.
To assess cognitive functions, participants completed a series of online tests. Behavioral changes, or MBI, were also assessed online via a specialized questionnaire in the PROTECT platform.
Dr. Byron Creese, of the University of Exeter, said: “This research adds to the growing evidence that some people who experience suspicious thoughts or become withdrawn in later life have more memory and thinking problems. The findings are important because they suggest that monitoring these symptoms could help identify people memory problems early on. The research also highlights the importance of gender differences in these relationships.”
Dr. Wolfová added that although there is currently no cure, patients might benefit from early diagnosis through secondary prevention and development of a comprehensive care plan. Identification of patients with preclinical Alzheimer’s disease is extremely important for clinical trials, as researchers need to screen potential participants with expensive biomarker tests before they can enroll them in a study. Screening with MBI to assess whether candidates are suitable for a trial might save a lot of money, and optimization of this process to reflect differences between men and women could further increase precision and reduce costs.
Photo: Katrin Wolfová (credit: Charles University in Prague)
NOTES FOR EDITORS
Full study: “Gender/Sex Differences in the Association of Mild Behavioral Impairment with Cognitive Aging” by Katrin Wolfova, Byron Creese, Dag Aarsland, Zahinoor Ismail, Anne Corbett, Clive Ballard, Adam Hampshire, and Pavla Cermakova (DOI: 10.3233/JAD-220040), published in the Journal of Alzheimer’s Disease, Volume 88, Issue 1. The article is available at: content.iospress.com/articles/journal-of-alzheimers-disease/jad220040.
The study was funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London, the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South West Peninsula and the National Institute for Health Research (NIHR) Exeter Clinical Research Facility. The first and corresponding authors were supported by the Czech Ministry of Health and the Czech Alzheimer Endowment Fund.
Further information can be obtained from Pavla Čermáková, PhD, Karlova Univerzita (firstname.lastname@example.org).
About the Journal of Alzheimer’s Disease
Now in its 25th year of publication, the Journal of Alzheimer’s Disease (JAD) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment, and psychology of Alzheimer’s disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease, and clinical trial outcomes. JAD has a Journal Impact Factor of 4.160 according to Journal Citation Reports (Clarivate, 2022). The journal is published by IOS Press. j-alz.com
About IOS Press
IOS Press is an independent international scientific, technical, medical (STM) publishing house established in 1987 in Amsterdam. We produce around 90 journals and 70 books annually in a broad range of subject categories, primarily specializing in biomedical and life sciences (including neurosciences, medical informatics, cancer research, rehabilitation) and physical sciences (including computer sciences, artificial intelligence, engineering). In addition, we offer specialized services that support scientific advancement. iospress.com